Instituto RosenbuschBUE:ROSE 39 Gross Margin % is 13.71% as of Dec. 2025, which is 56% below its 10-year median of 31.12. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.84 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 936 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 98.61% on this metric.
The historical rank and industry rank for Instituto Rosenbusch's Gross Margin % or its related term are showing as below:
BUE:ROSE'
s Gross Margin % Range Over the Past 10 Years
Min: -9.35 Med: 31.12 Max: 46.75
Current: -9.35
During the past 13 years, the highestGross Margin % of Instituto Rosenbusch was 46.75%. The lowest was -9.35%. And the median was 31.12%.
BUE:ROSE's Gross Margin % is ranked worse than 98.61% of 936
companies
in the Drug Manufacturers industry
Industry Median: 48.5
vs BUE:ROSE: -9.35
Instituto Rosenbusch had a gross margin of 13.71% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Instituto Rosenbusch was 0.00% per year.
Instituto Rosenbusch (BUE:ROSE) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Instituto Rosenbusch had a gross margin of 13.71% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Instituto Rosenbusch Gross Margin % Related Terms
Instituto Rosenbusch Gross Margin % Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Instituto Rosenbusch (BUE:ROSE) has a Gross Margin % of 13.71% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Instituto Rosenbusch and its competitors. This is 56% below median its historical median of 31.12. According to the industry distribution chart, Instituto Rosenbusch ranks #923 out of 936 companies in the Drug Manufacturers industry, placing it in the top 98.6%.
Is Instituto Rosenbusch's Gross Margin % too high?
Instituto Rosenbusch's current Gross Margin % of 13.71% is 56% below median its 10-year median of 31.12. The Drug Manufacturers industry median Gross Margin % is 48.50. Instituto Rosenbusch's value of 13.71% is 71.7% below this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #923 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #923 out of 936 companies for Gross Margin %. This places Instituto Rosenbusch in the lower half of its industry. The industry median Gross Margin % is 48.50. Instituto Rosenbusch's value of 13.71% is 71.7% below this benchmark. While the company's 10-year median is 31.12 vs. the industry median of 48.50, Instituto Rosenbusch has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current Gross Margin % of 13.71% is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Gross Margin % is 13.71%, which is 56% below median its own 10-year median of 31.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.84, compared to a current price of ARS163.00 — trading 163.6% above its estimated fair value. The current Gross Margin % is 13.71%, which is 56% below median its 10-year median of 31.12 and 71.7% below the Drug Manufacturers industry median of 48.50. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Gross Margin % is 13.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS163.00 is trading 163.6% above its estimated GF Value™ of ARS61.84.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Gross Margin %: 13.71% (56% below median its 10-year median of 31.12)
GF Value™: ARS61.84 vs. price of ARS163.00 (163.6% above fair value)
Industry Position: 71.7% below the Drug Manufacturers median (#923 of 936)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score
Get the complete analysis for BUE:ROSE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
